{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:48:37Z","timestamp":1784958517244,"version":"3.55.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02621-8","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T08:32:06Z","timestamp":1739781126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ovarian cancer and its management through advanced drug delivery system"],"prefix":"10.1007","volume":"42","author":[{"given":"Sujit","family":"Bose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachana","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2621_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.matbio.2023.02.004","volume":"118","author":"Y Brown","year":"2023","unstructured":"Brown Y, Hua S, Tanwar PS. Extracellular matrix in high-grade serous ovarian cancer: advances in understanding of carcinogenesis and cancer biology. Matrix Biol. 2023;118:16\u201346.","journal-title":"Matrix Biol"},{"key":"2621_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jconrel.2018.05.012","volume":"283","author":"D van den Brand","year":"2018","unstructured":"van den Brand D, Mertens V, Massuger LFAG, Brock R. siRNA in ovarian cancer\u2013delivery strategies and targets for therapy. J Control Release. 2018;283:45\u201358.","journal-title":"J Control Release"},{"key":"2621_CR3","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.adcanc.2022.100040","volume":"4","author":"AH Lee","year":"2022","unstructured":"Lee AH, Koh IL, Dawson MR. The role of exosome heterogeneity in epithelial ovarian cancer. Adv Cancer Biol Metastasis. 2022;4:100040.","journal-title":"Adv Cancer Biol Metastasis"},{"issue":"3","key":"2621_CR4","doi-asserted-by":"publisher","first-page":"100149","DOI":"10.1016\/j.esmoop.2021.100149","volume":"6","author":"SI Kim","year":"2021","unstructured":"Kim SI, Kim JW. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. ESMO Open. 2021;6(3):100149.","journal-title":"ESMO Open"},{"key":"2621_CR5","doi-asserted-by":"publisher","first-page":"102198","DOI":"10.1016\/j.jddst.2020.102198","volume":"61","author":"A Zafar","year":"2021","unstructured":"Zafar A, Alruwaili NK, Imam SS, Alharbi KS, Afzal M, Alotaibi NH, et al. Novel nanotechnology approaches for diagnosis and therapy of breast, ovarian and cervical cancer in female: a review. J Drug Deliv Sci Technol. 2021;61:102198.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"2621_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2621_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"2621_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jconrel.2019.08.034","volume":"311\u2013312","author":"AM Khalifa","year":"2019","unstructured":"Khalifa AM, Elsheikh MA, Khalifa AM, Elnaggar YSR. Current strategies for different paclitaxel-loaded nano-delivery systems towards therapeutic applications for ovarian carcinoma: a review article. J Control Release. 2019;311\u2013312:125\u201337.","journal-title":"J Control Release"},{"key":"2621_CR9","doi-asserted-by":"publisher","first-page":"117084","DOI":"10.1016\/j.envres.2023.117084","volume":"237","author":"FD Moghaddam","year":"2023","unstructured":"Moghaddam FD, Dadgar D, Esmaeili Y, Babolmorad S, Ilkhani E, Rafiee M, et al. Microfluidic platforms in diagnostic of ovarian cancer. Environ Res. 2023;237:117084.","journal-title":"Environ Res"},{"issue":"2","key":"2621_CR10","first-page":"157","volume":"139","author":"JK Chan","year":"2022","unstructured":"Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, et al. Symptoms of women with high-risk early-stage ovarian cancer. Obstet Gynecol. 2022;139(2):157\u201362.","journal-title":"Obstet Gynecol"},{"key":"2621_CR11","unstructured":"Ovarian Cancer By The Numbers, OCRA. https:\/\/ocrahope.org\/get-the-facts\/statistics\/"},{"key":"2621_CR12","doi-asserted-by":"publisher","DOI":"10.47611\/jsrhs.v11i2.2628","author":"R Davar","year":"2022","unstructured":"Davar R, Yalamanchili M. Identification of a panel of biomarkers for the early detection of ovarian cancer. J Stud Res. 2022. https:\/\/doi.org\/10.47611\/jsrhs.v11i2.2628.","journal-title":"J Stud Res"},{"issue":"3","key":"2621_CR13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.gendis.2022.07.004","volume":"10","author":"K Utkarsh","year":"2023","unstructured":"Utkarsh K, Kumar A, Aditi KA, Nayyar A, Haque S, et al. Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer. Gene Dis. 2023;10(3):1005\u201318.","journal-title":"Gene Dis."},{"key":"2621_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","volume":"41","author":"PM Webb","year":"2017","unstructured":"Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3\u201314.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"2621_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00404-019-05358-8","volume":"301","author":"M Kr\u00e1l\u00ed\u010dkov\u00e1","year":"2020","unstructured":"Kr\u00e1l\u00ed\u010dkov\u00e1 M, Lagan\u00e0 AS, Ghezzi F, Vetvicka V. Endometriosis and risk of ovarian cancer: what do we know? Arch Gynecol Obstet. 2020;301(1):10.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"2621_CR16","first-page":"335","volume":"26","author":"N Khanlarkhani","year":"2022","unstructured":"Khanlarkhani N, Azizi E, Amidi F, Khodarahmian M, Salehi E, Pazhohan A, Farhood B, Mortezae K, Goradel NH, Nashtaei MS. Metabolic risk factors of ovarian cancer: a review. JBRA Assist Reprod. 2022;26(2):335.","journal-title":"JBRA Assist Reprod"},{"issue":"1\u20132","key":"2621_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000479006","volume":"85","author":"M Kossa\u00ef","year":"2018","unstructured":"Kossa\u00ef M, Leary A, Scoazec JY, Genestie C. Ovarian cancer: a heterogeneous disease. Pathobiology. 2018;85(1\u20132):41\u20139.","journal-title":"Pathobiology"},{"issue":"4","key":"2621_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jcsm.12311","volume":"9","author":"F Pin","year":"2018","unstructured":"Pin F, Barreto R, Kitase Y, Mitra S, Erne CE, Novinger LJ, et al. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle. 2018;9(4):685\u2013700.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"12","key":"2621_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22126532","volume":"22","author":"S Morand","year":"2021","unstructured":"Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine. Int J Mol Sci. 2021;22(12):1\u201319.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"2621_CR20","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1158\/1078-0432.CCR-18-3720","volume":"25","author":"C Bodelon","year":"2019","unstructured":"Bodelon C, Killian JK, Sampson JN, Anderson WF, Matsuno R, Brinton LA, Lissowska J, Anglesio MS, Bowtell DD, Doherty JA, Ramus SJ. Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity. Clin Cancer Res. 2019;25(19):5937\u201346.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2621_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433\u201343.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2621_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","volume":"186","author":"RJ Kurman","year":"2016","unstructured":"Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Surg Pathol. 2016;186(4):733\u201347.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2621_CR23","first-page":"53","volume":"151","author":"LC Peres","year":"2019","unstructured":"Peres LC, Cushing-haugen KL, Anglesio M, Wicklund K, Berchuck A, Kelemen LE, et al. HHS Public Access. 2019;151(1):53\u201360.","journal-title":"HHS Public Access"},{"issue":"13","key":"2621_CR24","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra1813254","volume":"380","author":"P Morice","year":"2019","unstructured":"Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. New Engl J Med. 2019;380(13):1256\u201366.","journal-title":"New Engl J Med"},{"issue":"10","key":"2621_CR25","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.ajhg.2021.09.003","volume":"108","author":"SM Caputo","year":"2021","unstructured":"Caputo SM, Golmard L, L\u00e9one M, Damiola F, Guillaud-Bataille M, Revillion F, et al. Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: a powerful approach. Am J Hum Genet. 2021;108(10):1907\u201323.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2621_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.path.2019.02.005","volume":"12","author":"KZ Hanley","year":"2019","unstructured":"Hanley KZ, Mosunjac MB. Practical review of ovarian sex cord-stromal tumors. Surg Pathol Clin. 2019;12(2):587\u2013620.","journal-title":"Surg Pathol Clin"},{"key":"2621_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2020.11.021","volume":"81","author":"K Ksi\u0105\u017cek","year":"2022","unstructured":"Ksi\u0105\u017cek K. Where does cellular senescence belong in the pathophysiology of ovarian cancer? Semin Cancer Biol. 2022;81:14\u201323.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"2621_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms24108930","volume":"24","author":"G Tossetta","year":"2023","unstructured":"Tossetta G, Inversetti A. Ovarian cancer: advances in pathophysiology and therapies. Int J Mol Sci. 2023;24(10):23\u20135.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2621_CR29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3390\/cells9040814","volume":"9","author":"A Shimizu","year":"2020","unstructured":"Shimizu A, Sawada K, Kimura T. Pathophysiological role and potential therapeutic exploitation of exosomes in ovarian cancer. Cells. 2020;9(4):814.","journal-title":"Cells"},{"key":"2621_CR30","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00188.2015","author":"TL Yeung","year":"2015","unstructured":"Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. a review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015. https:\/\/doi.org\/10.1152\/ajpcell.00188.2015.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2621_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.trsl.2016.03.016","volume":"175","author":"LG Coffman","year":"2016","unstructured":"Coffman LG, Burgos-Ojeda D, Wu R, Cho K, Bai S, Buckanovich RJ. New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination. Transl Res. 2016;175:92\u2013102.","journal-title":"Transl Res"},{"issue":"11","key":"2621_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/cancers10110433","volume":"10","author":"J Kim","year":"2018","unstructured":"Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Jr. Cell origins of high-grade serous ovarian cancer. Cancers. 2018;10(11):433.","journal-title":"Cancers"},{"key":"2621_CR33","doi-asserted-by":"publisher","DOI":"10.23736\/S0031-0808.18.03494-8","author":"GM Bedoschi","year":"2019","unstructured":"Bedoschi GM, Navarro PA, Oktay KH. Novel insights into the pathophysiology of chemotherapy-induced damage to the ovary. Panminerva Med. 2019. https:\/\/doi.org\/10.23736\/S0031-0808.18.03494-8.","journal-title":"Panminerva Med"},{"key":"2621_CR34","doi-asserted-by":"publisher","first-page":"viii28","DOI":"10.1093\/annonc\/mdt308","volume":"24","author":"L Dubeau","year":"2013","unstructured":"Dubeau L, Drapkin R. 2013 Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol. 2013;24:viii28-35.","journal-title":"Ann Oncol"},{"issue":"4","key":"2621_CR35","first-page":"1","volume":"15","author":"C Shetty","year":"2023","unstructured":"Shetty C, Rizvi SMHA, Sharaf J, Williams KAD, Tariq M, Acharekar MV, et al. Risk of gynecological cancers in women with polycystic ovary syndrome and the pathophysiology of association. Cureus. 2023;15(4):1\u20138.","journal-title":"Cureus"},{"issue":"7","key":"2621_CR36","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1089\/omi.2018.0060","volume":"22","author":"A Konstorum","year":"2018","unstructured":"Konstorum A, Lynch ML, Torti SV, Torti FM, Laubenbacher RC. A systems biology approach to understanding the pathophysiology of high-grade serous ovarian cancer: focus on iron and fatty acid metabolism. Omi J Integr Biol. 2018;22(7):502\u201313.","journal-title":"Omi J Integr Biol"},{"issue":"12","key":"2621_CR37","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1470-2045(08)70308-5","volume":"9","author":"L Dubeau","year":"2008","unstructured":"Dubeau L. The cell of origin of ovarian epithelial tumors. Lancet Oncol. 2008;9(12):1191\u20137.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2621_CR38","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.hoc.2018.07.003","volume":"32","author":"KM Elias","year":"2018","unstructured":"Elias KM, Guo J, Bast RC. Early detection of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):903\u201314.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2621_CR39","doi-asserted-by":"crossref","unstructured":"Rampes S, Choy SP. Early diagnosis of symptomatic ovarian cancer in primary care in the UK: Opportunities and challenges. Prim Heal Care Res Dev. 2022;23.","DOI":"10.1017\/S146342362200041X"},{"issue":"4","key":"2621_CR40","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.sult.2019.04.002","volume":"40","author":"M Shetty","year":"2019","unstructured":"Shetty M. Imaging and differential diagnosis of ovarian cancer. Semin Ultrasound, CT MRI. 2019;40(4):302\u201318.","journal-title":"Semin Ultrasound, CT MRI"},{"issue":"1","key":"2621_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-023-01440-w","volume":"15","author":"SK Terp","year":"2023","unstructured":"Terp SK, Stoico MP, Dybk\u00e6r K, Pedersen IS. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review. Clin Epigenetics. 2023;15(1):1\u201317.","journal-title":"Clin Epigenetics"},{"key":"2621_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221114497","author":"K Dong","year":"2021","unstructured":"Dong K, Zhang W, Cheng S, Shu W, Zhao R, Wang H. The progress of the specific and rapid genetic detection methods for ovarian cancer diagnosis and treatment. Technol Cancer Res Treat. 2021. https:\/\/doi.org\/10.1177\/15330338221114497.","journal-title":"Technol Cancer Res Treat"},{"issue":"5","key":"2621_CR43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/AOG.0000000000002580","volume":"131","author":"U Menon","year":"2018","unstructured":"Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian cancer prevention and screening. Obstet Gynecol. 2018;131(5):909\u201327.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2621_CR44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ygyno.2020.11.018","volume":"160","author":"E Hulstaert","year":"2021","unstructured":"Hulstaert E, Morlion A, Levanon K, Vandesompele J, Mestdagh P. Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: a systematic review. Gynecol Oncol. 2021;160(2):633\u201342.","journal-title":"Gynecol Oncol"},{"key":"2621_CR45","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s12094-018-1967-4","volume":"21","author":"L Minig","year":"2019","unstructured":"Minig L, De Santiago J, Domingo S, Gil-Moreno A, Mart\u00ednez S, Rodr\u00edguez-Garzotto A, Chiva L. Optimization of surgical treatment of advanced ovarian cancer: a Spanish expert perspective. Clin Transl Oncol. 2019;21:656\u201364.","journal-title":"Clin Transl Oncol"},{"key":"2621_CR46","first-page":"1","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. British Med J. 2020;371:1\u201320.","journal-title":"British Med J"},{"issue":"5","key":"2621_CR47","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/annonc\/mdz104","volume":"30","author":"M Buechel","year":"2019","unstructured":"Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol. 2019;30(5):721\u201332.","journal-title":"Ann Oncol"},{"issue":"7","key":"2621_CR48","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00432-021-03629-z","volume":"147","author":"D Huber","year":"2021","unstructured":"Huber D, Seitz S, Kast K, Emons G, Ortmann O. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review. J Cancer Res Clin Oncol. 2021;147(7):2035\u201345.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2621_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-018-0602-0","volume":"11","author":"S Moufarrij","year":"2019","unstructured":"Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-Acevedo M, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11(1):1\u201311.","journal-title":"Clin Epigenetics"},{"issue":"2","key":"2621_CR50","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","volume":"162","author":"A Alvarez Secord","year":"2021","unstructured":"Alvarez Secord A, O\u2019Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review. Gynecol Oncol. 2021;162(2):482\u201395.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"2621_CR51","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.3390\/ijerph19074260","volume":"19","author":"A Ferrero","year":"2022","unstructured":"Ferrero A, Borghese M, Restaino S, Puppo A, Vizzielli G, Biglia N. Predicting response to anthracyclines in ovarian cancer. Int J Environ Res Public Health. 2022;19(7):4260.","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"2621_CR52","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/CAD.0000000000000793","volume":"30","author":"L Liu","year":"2019","unstructured":"Liu L, Liu P, Liang Z, Li R, Shen M, Xu H, et al. Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer. Anticancer Drugs. 2019;30(6):554\u201361.","journal-title":"Anticancer Drugs"},{"key":"2621_CR53","doi-asserted-by":"crossref","unstructured":"Perez-Fidalgo JA, Grau F, Fari\u00f1as L, Oaknin A. Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: from chemotherapy to precision medicine. Crit Rev Oncol Hematol. 2021;158.","DOI":"10.1016\/j.critrevonc.2020.103209"},{"issue":"5","key":"2621_CR54","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620\u201331.","journal-title":"Lancet Oncol"},{"key":"2621_CR55","doi-asserted-by":"publisher","first-page":"114304","DOI":"10.1016\/j.biopha.2023.114304","volume":"160","author":"Y Xie","year":"2023","unstructured":"Xie Y, Ren Z, Chen H, Tang H, Zhu M, Lv Z, et al. A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer. Biomed Pharmacother. 2023;160:114304.","journal-title":"Biomed Pharmacother"},{"key":"2621_CR56","doi-asserted-by":"publisher","first-page":"114092","DOI":"10.1016\/j.bcp.2020.114092","volume":"178","author":"Q Feng","year":"2020","unstructured":"Feng Q, Li X, Sun W, Sun M, Li Z, Sheng H, et al. Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1. Biochem Pharmacol. 2020;178:114092.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"2621_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12040965","volume":"12","author":"B Layek","year":"2020","unstructured":"Layek B, Shetty M, Nethi SK, Sehgal D, Starr TK, Prabha S. Mesenchymal stem cells as guideposts for nanoparticle-mediated targeted drug delivery in ovarian cancer. Cancers. 2020;12(4):1\u201318.","journal-title":"Cancers"},{"issue":"3","key":"2621_CR58","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1039\/C8TB02574F","volume":"7","author":"H Song","year":"2019","unstructured":"Song H, Quan F, Yu Z, Zheng M, Ma Y, Xiao H, et al. Carboplatin prodrug conjugated Fe 3 O 4 nanoparticles for magnetically targeted drug delivery in ovarian cancer cells. J Mater Chem B. 2019;7(3):433\u201342.","journal-title":"J Mater Chem B"},{"key":"2621_CR59","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2147\/DDDT.S195493","volume":"13","author":"S Li","year":"2019","unstructured":"Li S, Li X, Ding J, Han L, Guo X. Anti-tumor efficacy of folate modified PLGA-based nanoparticles for the co-delivery of drugs in ovarian cancer. Drug Des Devel Ther. 2019;13:1271\u201380.","journal-title":"Drug Des Devel Ther"},{"key":"2621_CR60","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.2147\/DDDT.S248950","volume":"14","author":"Q Long","year":"2020","unstructured":"Long Q, Zhu W, Guo L, Pu L. RGD-conjugated resveratrol HSA nanoparticles as a novel delivery system in ovarian cancer therapy. Drug Des Devel Ther. 2020;14:5747\u201356.","journal-title":"Drug Des Devel Ther"},{"key":"2621_CR61","doi-asserted-by":"publisher","first-page":"119219","DOI":"10.1016\/j.biomaterials.2019.05.030","volume":"213","author":"T Qi","year":"2019","unstructured":"Qi T, Chen B, Wang Z, Du H, Liu D, Yin Q, et al. A pH-Activatable nanoparticle for dual-stage precisely mitochondria-targeted photodynamic anticancer therapy. Biomater. 2019;213:119219.","journal-title":"Biomater"},{"issue":"2","key":"2621_CR62","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ijpharm.2015.10.080","volume":"496","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Guo J, Zhang XL, Li DP, Zhang TT, Gao FF, et al. Antibody fragment-armed mesoporous silica nanoparticles for the targeted delivery of bevacizumab in ovarian cancer cells. Int J Pharm. 2015;496(2):1026\u201333.","journal-title":"Int J Pharm"},{"issue":"14","key":"2621_CR63","doi-asserted-by":"publisher","first-page":"11575","DOI":"10.3390\/ijms241411575","volume":"24","author":"L Chen","year":"2023","unstructured":"Chen L, Luo J, Zhang J, Wang S, Sun Y, Liu Q, et al. Dual targeted nanoparticles for the codelivery of doxorubicin and siRNA cocktails to overcome ovarian cancer stem cells. Int J Mol Sci. 2023;24(14):11575.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2621_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-41122-3","volume":"9","author":"KA Mills","year":"2019","unstructured":"Mills KA, Quinn JM, Roach ST, Palisoul M, Nguyen M, Noia H, et al. p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts. Sci Rep. 2019;9(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"3","key":"2621_CR65","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3892\/ijo.2015.3079","volume":"47","author":"Z Li","year":"2015","unstructured":"Li Z, Sun L, Lu Z, Su X, Yang Q, Qu X, et al. Enhanced effect of photodynamic therapy in ovarian cancer using a nanoparticle drug delivery system. Int J Oncol. 2015;47(3):1070\u20136.","journal-title":"Int J Oncol"},{"issue":"1","key":"2621_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-021-01139-1","volume":"19","author":"X Wang","year":"2021","unstructured":"Wang X, Xiong T, Cui M, Li N, Li Q, Zhu L, et al. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway. J Nanobiotechnol. 2021;19(1):1\u201318.","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"2621_CR67","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.nano.2016.11.010","volume":"13","author":"CM Roberts","year":"2017","unstructured":"Roberts CM, Shahin SA, Wen W, Finlay JB, Dong J, Wang R, et al. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanomed Nanotechnol Biol Med. 2017;13(3):965\u201376.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"1","key":"2621_CR68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ygyno.2014.06.030","volume":"135","author":"L Fan","year":"2014","unstructured":"Fan L, Chen J, Zhang X, Liu Y, Xu C. Follicle-stimulating hormone polypeptide modified nanoparticle drug delivery system in the treatment of lymphatic metastasis during ovarian carcinoma therapy. J Gynecol Oncol. 2014;135(1):125\u201332.","journal-title":"J Gynecol Oncol"},{"key":"2621_CR69","doi-asserted-by":"publisher","first-page":"115573","DOI":"10.1016\/j.biopha.2023.115573","volume":"167","author":"R Zhou","year":"2023","unstructured":"Zhou R, You Y, Zha Z, Chen J, Li Y, Chen X, et al. Biotin decorated celastrol-loaded ZIF-8 nano-drug delivery system targeted epithelial ovarian cancer therapy. Biomed Pharmacother. 2023;167:115573.","journal-title":"Biomed Pharmacother"},{"key":"2621_CR70","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1080\/10837450.2020.1823992","volume":"25","author":"G Ya\u015fayan","year":"2020","unstructured":"Ya\u015fayan G, Mega Tiber P, Orun O, Alar\u00e7in E. Doxorubicin hydrochloride loaded nanotextured films as a novel drug delivery platform for ovarian cancer treatment. Pharm Dev Technol. 2020;25:1289\u2013301.","journal-title":"Pharm Dev Technol"},{"issue":"11","key":"2621_CR71","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1021\/acs.molpharmaceut.1c00514","volume":"18","author":"K Yamaguchi","year":"2021","unstructured":"Yamaguchi K, Hiraike O, Iwaki H, Matsumiya K, Nakamura N, Sone K, et al. Intraperitoneal administration of a cisplatin-loaded nanogel through a hybrid system containing an alginic acid-based nanogel and an in situ cross-linkable hydrogel for peritoneal dissemination of ovarian cancer. Mol Pharm. 2021;18(11):4090\u20138.","journal-title":"Mol Pharm"},{"issue":"sup1","key":"2621_CR72","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1080\/21691401.2018.1439838","volume":"46","author":"G Ak","year":"2018","unstructured":"Ak G, Yilmaz H, G\u00fcne\u015f A, Hamarat SS. In vitro and in vivo evaluation of folate receptor-targeted a novel magnetic drug delivery system for ovarian cancer therapy. Artif Cells Nanomed Biotechnol. 2018;46(sup1):926\u201337.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"7","key":"2621_CR73","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1080\/15384047.2017.1395118","volume":"19","author":"NR Patel","year":"2018","unstructured":"Patel NR, Piroyan A, Ganta S, Morse AB, Candiloro KM, Solon AL, Nack AH, Galati CA, Bora C, Maglaty MA, O\u2019Brien SW. In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers. Cancer Biol & Ther. 2018;19(7):554\u201364.","journal-title":"Cancer Biol & Ther"},{"issue":"2","key":"2621_CR74","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1248\/cpb.c14-00423","volume":"63","author":"W Lv","year":"2015","unstructured":"Lv W, Cheng L, Li B. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer. Chem Pharm Bull. 2015;63(2):68\u201374.","journal-title":"Chem Pharm Bull"},{"key":"2621_CR75","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.colsurfb.2019.03.037","volume":"178","author":"H Tiwari","year":"2019","unstructured":"Tiwari H, Karki N, Pal M, Basak S, Verma RK, Bal R, et al. Functionalized graphene oxide as a nanocarrier for dual drug delivery applications: the synergistic effect of quercetin and gefitinib against ovarian cancer cells. Colloids Surf B Biointerfaces. 2019;178:452\u20139.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"41","key":"2621_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/smll.202102494","volume":"17","author":"H Lu","year":"2021","unstructured":"Lu H, Zhang Q, He S, Liu S, Xie Z, Li X, et al. Reduction-Sensitive Fluorinated-Pt(IV) universal transfection nanoplatform facilitating CT45-Targeted CRISPR\/dCas9 activation for synergistic and individualized treatment of ovarian cancer. Small. 2021;17(41):1\u201311.","journal-title":"Small"},{"key":"2621_CR77","first-page":"2849","volume":"13","author":"Y Huang","year":"2021","unstructured":"Huang Y, Xu J, Li K, Wang J, Dai Y, Kang Y. A novel, personalized drug-screening system for platinum-resistant ovarian cancer patients: a preliminary clinical report. Cancer Mang Res. 2021;13:2849\u201367.","journal-title":"Cancer Mang Res"},{"key":"2621_CR78","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-2759-4","author":"NB Mutlu-Agardan","year":"2020","unstructured":"Mutlu-Agardan NB, Sarisozen C, Torchilin VP. Cytotoxicity of novel redox sensitive PEG2000-S-S-PTX micelles against drug-resistant ovarian and breast cancer cells. Pharm Res. 2020. https:\/\/doi.org\/10.1007\/s11095-020-2759-4.","journal-title":"Pharm Res"},{"issue":"4","key":"2621_CR79","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1158\/1535-7163.MCT-14-0556","volume":"14","author":"G Salzano","year":"2015","unstructured":"Salzano G, Navarro G, Trivedi MS, De Rosa G, Torchilin VP. Multifunctional polymeric micelles co-loaded with anti\u2013survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer. Mol Cancer Ther. 2015;14(4):1075\u201384.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2621_CR80","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3892\/or.2015.4066","volume":"34","author":"C Yang","year":"2015","unstructured":"Yang C, He X, Liu X, Tang Z, Liang X. OSTP as a novel peptide specifically targeting human ovarian cancer. Oncol Rep. 2015;34(2):972\u20138.","journal-title":"Oncol Rep"},{"issue":"7","key":"2621_CR81","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.nano.2015.05.007","volume":"11","author":"G Song","year":"2015","unstructured":"Song G, Tarrant TK, White TF, Barrow DA, Santos CM, Timoshchenko RG, et al. Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. Nanomed Nanotechnol Biol Med. 2015;11(7):1797\u2013807.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"5","key":"2621_CR82","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3892\/ijmm.2014.1922","volume":"34","author":"XJ Han","year":"2014","unstructured":"Han XJ, Wei YF, Wan YY, Jiang LP, Zhang JF, Xin HB. Development of a novel liposomal nanodelivery system for bioluminescence imaging and targeted drug delivery in ErbB2-overexpressing metastatic ovarian carcinoma. Int J Mol Med. 2014;34(5):1225\u201332.","journal-title":"Int J Mol Med"},{"key":"2621_CR83","doi-asserted-by":"publisher","first-page":"118729","DOI":"10.1016\/j.ijpharm.2019.118729","volume":"573","author":"S Vandghanooni","year":"2020","unstructured":"Vandghanooni S, Eskandani M, Barar J, Omidi Y. Antisense LNA-loaded nanoparticles of star-shaped glucose-core PCL-PEG copolymer for enhanced inhibition of oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant ovarian cancer cells. Int J Pharm. 2020;573:118729.","journal-title":"Int J Pharm"},{"issue":"1","key":"2621_CR84","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1080\/10717544.2022.2105443","volume":"29","author":"W Liwinska","year":"2022","unstructured":"Liwinska W, Waleka-Bagiel E, Stojek Z, Karbarz M, Zabost E. Enzyme-triggered- and tumor-targeted delivery with tunable, methacrylated poly(ethylene glycols) and hyaluronic acid hybrid nanogels. Drug Deliv. 2022;29(1):2561\u201378.","journal-title":"Drug Deliv"},{"key":"2621_CR85","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/IJN.S152474","volume":"13","author":"E Ghassami","year":"2018","unstructured":"Ghassami E, Varshosaz J, Jahanian-Najafabadi A, Minaiyan M, Rajabi P, Hayati E. Pharmacokinetics and in vitro\/in vivo antitumor efficacy of aptamer-targeted ecoflex\u00ae nanoparticles for docetaxel delivery in ovarian cancer. Int J Nanomed. 2018;13:493\u2013504.","journal-title":"Int J Nanomed"},{"key":"2621_CR86","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jconrel.2015.11.004","volume":"220","author":"Y Liu","year":"2015","unstructured":"Liu Y, Ng Y, Toh MR, Chiu GNC. Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer. J Controlled Release. 2015;220:438\u201346.","journal-title":"J Controlled Release"},{"issue":"1","key":"2621_CR87","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbrc.2020.04.076","volume":"527","author":"M Kobayashi","year":"2020","unstructured":"Kobayashi M, Sawada K, Miyamoto M, Shimizu A, Yamamoto M, Kinose Y, Nakamura K, Kawano M, Kodama M, Hashimoto K, Kimura T. Exploring the potential of engineered exosomes as delivery systems for tumor-suppressor microRNA replacement therapy in ovarian cancer. Biochem Biophys Res Commun. 2020;527(1):153\u201361.","journal-title":"Biochem Biophys Res Commun"},{"key":"2621_CR88","doi-asserted-by":"crossref","unstructured":"Yang S, Green A, Brown N, Robinson A, Senat M, Testino B, et al. Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer. Front Oncol. 2023;1\u201312.","DOI":"10.3389\/fonc.2023.1175617"},{"issue":"1","key":"2621_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-14788-5","volume":"12","author":"A Wallace-Povirk","year":"2022","unstructured":"Wallace-Povirk A, Rubinsak L, Malysa A, Dzinic SH, Ravindra M, Schneider M, et al. Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment. Sci Rep. 2022;12(1):1\u201315.","journal-title":"Sci Rep"},{"issue":"1","key":"2621_CR90","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1080\/10717544.2018.1440444","volume":"25","author":"CE Chang","year":"2018","unstructured":"Chang CE, Hsieh CM, Chen LC, Su CY, Liu DZ, Jhan HJ, et al. Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer. J Drug Deliv. 2018;25(1):632\u201343.","journal-title":"J Drug Deliv"},{"key":"2621_CR91","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.actbio.2023.12.020","volume":"175","author":"N Song","year":"2024","unstructured":"Song N, Sun Z, Wang B, Liu X, Hu B, Chen N, et al. Suicide gene delivery by morphology-adaptable enantiomeric peptide assemblies for combined ovarian cancer therapy. Acta Biomater. 2024;175:250\u201361.","journal-title":"Acta Biomater"},{"key":"2621_CR92","first-page":"1","volume":"14","author":"HM Alharbi","year":"2023","unstructured":"Alharbi HM, Alqahtani T, Alamri AH, Kumarasamy V, Subramaniyan V, Babu KS. Nanotechnological synergy of mangiferin and curcumin in modulating PI3K\/Akt\/mTOR pathway: a novel front in ovarian cancer precision therapeutics. Front Pharmacol. 2023;14:1\u201311.","journal-title":"Front Pharmacol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02621-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02621-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02621-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:25:32Z","timestamp":1741271132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02621-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":92,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["2621"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02621-8","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article category is incorrect. The article category of this article should be \u201cReview Article\u201d.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"76"}}